All articles
Mounjaro® vs Wegovy® For Weight Loss
Reading time:
5 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Who is Eligible for Wegovy® and Mounjaro®
Wegovy® and Mounjaro® can be extremely effective weight loss tools for:
Those struggling with obesity (BMI ≥ 30)
Those who struggle with being overweight (BMI > 27) and have a weight-related health condition such as diabetes, high blood pressure, and or high cholesterol.
Do not use Wegovy® or Mounjaro® if:
You or a family member has had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have been diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have had a severe allergic reaction to semaglutide or tirzepatide (the primary active ingredients in Wegovy® and Mounjaro®, respectively).
Consult with a professional at Mochi to determine which weight loss medication is right for you.
Cost and Coverage of Wegovy® vs Mounjaro®
Both Wegovy® and Mounjaro® are expensive medications. A cost analysis study conducted in 2022 showed that Mounjaro® showed a better value for money than Wegovy® (4). However, it should be noted that both medications can be expensive, with Mounjaro® estimated at $17,000 and Wegovy® at $22,000 after 72 weeks of therapy. Some insurance plans may cover these medications to make costs more manageable. However, it is more difficult to get insurance coverage for Mounjaro® for weight loss since the FDA has not approved it for use in obesity in non-diabetic patients. On the other hand, Wegovy® is approved for obesity, which may make finding coverage by insurance more likely.
Mochi Health works with each patient individually to find the most affordable option. If you’re uninsured and still interested in starting weight loss medication, Mochi has safe and effective alternatives.
Conclusion
In summary, Wegovy® and Mounjaro® have both been shown to be effective at managing obesity. While they both target hormones that regulate appetite and satiety, they differ in their mechanism of action, dosage, administration, effectiveness, and cost. Patients and healthcare providers should carefully consider these differences when deciding which medication to take. It's also important to note that these medications should be combined with lifestyle modifications, such as diet and exercise, for the best results. If you are considering using Wegovy® or Mounjaro®, talk to your healthcare provider to determine which medication is right for you.
If you want to learn more about GLP-1 medications or want to see if you might be eligible for medication-assisted weight loss, contact the board-certified experts at Mochi Health.
References:
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
Azuri, J, Hammerman, A, Aboalhasan, E, Sluckis, B, Arbel, R. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obes Metab. 2023; 25( 4): 961- 964. doi:10.1111/dom.14940
Share this post
Weight loss
More articles















